ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors
April 12 2022 - 07:00AM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced the appointment
of Itziar Canamasas, Ph.D., to its Board of Directors (the “Board”)
effective April 11, 2022. With more than 20 years of
biopharmaceutical industry experience, Dr. Canamasas brings
expertise in driving business growth and operational excellence.
“We are excited to welcome Dr. Canamasas to our Board during an
important time in ALX Oncology’s continued evolution,” said Corey
Goodman, Ph.D., Executive Chairman of ALX Oncology. “Dr. Canamasas
provides a proven track record of successful oncology product
launches and transformational strategic expertise to ALX Oncology
that will be instrumental in 2022 and beyond as we execute on
helping patients fight cancer.”
“I am excited to join the Board at this pivotal junction in ALX
Oncology’s growth trajectory. I look forward to working closely
with the management team and fellow Board members to execute on
advancing evorpacept to reach its full potential as a therapy for
patients with hematological and solid tumors,” said Dr.
Canamasas.
Dr. Canamasas currently serves as the Head of Oncology Europe,
Middle East and Africa at Bayer AG. During her 20 plus years at
Bayer, Dr. Canamasas has held various oncology leadership positions
with expertise focused on global commercialization, strategic
life-cycle development and corporate strategy, including roles as
Vice President of Global Marketing Oncology and Managing Director
of Bayer Limited. Dr. Canamasas is also the Organizational
Development Director for the Ambassador Program at the Healthcare
Businesswomen’s Association (HBA). Dr. Canamasas holds a M.S. in
Biology with distinction from the Universitat de Barcelona and a
Ph.D. in Cancer Genetics from the University of Mainz.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage
immuno-oncology company focused on helping patients fight cancer by
developing therapies that block the CD47 checkpoint pathway and
bridge the innate and adaptive immune system. ALX Oncology’s lead
product candidate, evorpacept, is a next generation CD47 blocking
therapeutic that combines a high-affinity CD47 binding domain with
an inactivated, proprietary Fc domain. Evorpacept has demonstrated
promising clinical responses across a range of hematologic and
solid malignancies in combination with a number of leading
anti-cancer agents. ALX Oncology intends to continue clinical
development of evorpacept for the treatment of multiple solid tumor
indications and hematologic malignancies, including acute myeloid
leukemia and myelodysplastic syndromes.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. Forward-looking
statements include statements regarding future results of
operations and financial position, business strategy, product
candidates, planned preclinical studies and clinical trials,
results of clinical trials, research and development costs,
regulatory approvals, timing and likelihood of success, plans and
objects of management for future operations, as well as statements
regarding industry trends. Such forward-looking statements are
based on ALX Oncology’s beliefs and assumptions and on information
currently available to it on the date of this press release.
Forward-looking statements may involve known and unknown risks,
uncertainties and other factors that may cause ALX Oncology’s
actual results, performance or achievements to be materially
different from those expressed or implied by the forward-looking
statements. These and other risks are described more fully in ALX
Oncology’s filings with the Securities and Exchange Commission
(“SEC”), including ALX Oncology’s Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and other documents ALX Oncology
files with the SEC from time to time. Except to the extent required
by law, ALX Oncology undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1716de1e-e259-4c38-b678-3559c19bd869
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Feb 2024 to Mar 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Mar 2023 to Mar 2024